

### Laboratory Service Report

#### 1-800-533-1710

Patient Name SAMPLEREPORT,LPA3P	Patient ID SA00060743	<b>Age</b> 47	Gender F	Order # SA00060743
Ordering Phys CLIENT,CLIENT				<b>DOB</b> 06/10/1966
Client Order # SA00060743	Account Information			Report Notes
Collected 08/14/2013 13:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 09/24/2013 12:10	Rochester, MN 55901			

Test	Flag Results	Unit	Reference Value	Perform Site*
Lymphocyte Proliferation, aCD3				
<b>RECEIVED:</b> 08/15/2013 21:45 <b>REPORTED:</b> 08/15	5/2013 21:56			
Viab of Lymphs at Day O	95	olo	>=75	MCR
Max Prolif, soluble aCD3 as % CD45	21.0	010	>=19.4	MCR
Max Prolif, soluble aCD3 as % CD3	23.0	8	>=20.3	MCR
Max Prolif, soluble aCD28 as % CD45	42.0	00	>=37.5	MCR
Max Prolif, soluble aCD28 as % CD3	45.0	00	>=44.6	MCR
Max Prolif, soluble IL2 as % CD45	46.0	00	>=41.7	MCR
Max Prolif, soluble IL2 as % CD3	56.0	00	>=46.2	MCR
Interpretation				MCR
Normal.				

Clinical correlation recommended. Unable to provide further interpretation without clinical

information.

Reviewed by: Naren Hulsing 2013.08.15 09:56:21 Data are expressed as % proliferating cells of total specific cell population. The % Day 0 viability of the sample was determined using a flow cytometry assay which includes individual assessment of viable, apoptotic and dead cells. This method differs from the commonly used method of trypan blue dye exclusion which only identifies dead cells, and counts apoptotic cells along with the viable cells, resulting in an apparent higher cell viability. However, apoptotic cells do not contribute to cell proliferation and therefore accurate measurement of only viable cells provides meaningful information on the cells involved in stimulation and proliferative response. Strongly recommend using "critical ambient shipping boxes" available through Mayo Medical Laboratories (MML) inventory to ensure optimal transport of critical samples used for functional cellular assays.

This assay measures lymphocyte proliferative responses to an anti-CD3 panel. The stimulants include soluble anti-CD3 alone (3 titrations), soluble anti-CD3 + anti-CD28 (3 titrations) and soluble anti-CD3+ exogenous IL-2 (3 titrations). The maximal response to each stimulant is reported and includes % proliferation to both CD45+ total lymphocytes (equivalent of the response in the tritiated thymidine assay) and CD3+ T cells. Delta % proliferation is

#### \*\*\*Performing Site Legend on Last Page of Report\*\*\*

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,LPA3P	08/14/2013 13:00	Final
Page 1 of 2		>> Continued on Next Page >>

\* Report times for Mayo performed tests are CST/CDT



# Laboratory Service Report

## 1-800-533-1710

Patient Name SAMPLEREPORT,LPA3P	Patient ID SA00060743	<b>Age</b> 47	<b>Gender</b> F	<b>Order #</b> SA00060743
Ordering Phys CLIENT,CLIENT			<b>DOB</b> 06/10/1966	
Client Order # SA00060743	Account Information			Report Notes
Collected 08/14/2013 13:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 09/24/2013 12:10	Rochester, MN 55901			

Test	Flag Results	s Unif	Reference t Value	Perform Site*
reported for each value control. Analyte Specific Reagent performance characterist has not been cleared or	after subtraction from This test was developics determined by Mayo approved by the U.S. F	media ped and its Clinic. It ood and Drug		
Administration.				
aCD3 Comment				MCR
Lymphocyte proliferative age. Samples received b can show significant dec responses. Caution shou results and clinical cor Suggest repeat testing w Mononuclear cell prepara	responses are affected etween 24-48 hours pos- rease in lymphocyte pro- ld be used when interp- relation is strongly re- then clinically appropri- tion contains excess no base is clinically indi-	d by sample t-collection oliferative reting the ecommended. iate. eutrophils.		
Consider repeating this	test if clinically ind	icated.		

\* Performing Site:

200 First St SW Rochester, MN 55905
-------------------------------------

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT, LPA3P	08/14/2013 13:00	Final
Page 2 of 2		** End of Report **

\* Report times for Mayo performed tests are CST/CDT